Protagonist Therapeutics, Inc. Common Stock Earnings Dividend

Protagonist Therapeutics, Inc. Common Stock’s revenue jumped 3749.17% since last year same period to $213.48Mn in the Q2 2026. On a quarterly growth basis, Protagonist Therapeutics, Inc. Common Stock has generated 278.72% jump in its revenue since last 3-months.

Protagonist Therapeutics, Inc. Common Stock’s net profit jumped 568.35% since last year same period to $162.85Mn in the Q2 2026. On a quarterly growth basis, Protagonist Therapeutics, Inc. Common Stock has generated 4204.76% jump in its net profits since last 3-months.

Protagonist Therapeutics, Inc. Common Stock’s net profit margin jumped 112.17% since last year same period to 76.28% in the Q2 2026. On a quarterly growth basis, Protagonist Therapeutics, Inc. Common Stock has generated 1036.67% jump in its net profit margins since last 3-months.

Protagonist Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 2.19 - a 3.79% jump from last quarter’s estimates.

Protagonist Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 2.19.

Protagonist Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 516.36% since last year same period to 2.29 in the Q2 2026. This indicates that the Protagonist Therapeutics, Inc. Common Stock has generated 516.36% annual rate of jump in its earning per share (EPS) in the last 4 quarters.